AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial R

Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77, an Increase of 16.4 Percent; These Results...

Related Keywords

United States , American , Linzess Constella , Alphagan Combigan , Richarda Gonzalez , Lumigan Ganfort , Janssen Biotech Inc , Genentech , Twitter , Boehringer Ingelheim , American Heart Association Scientific Sessions , American College Of Rheumatology , American Society Of Hematology , European Union , Allergan , Abbvie Inc , Drug Administration , European Commission , Gedeon Richter Plc , Hotspot Therapeutics Inc , European Headache Federation Congress , Exchange Commission , European Medicines Agency , Roche Group , Reports Full Year Diluted , Adjusted Diluted , These Results Include , Unfavorable Impact , Full Year Net Revenues , Reported Basis , Year Global Net Revenues , Immunology Portfolio Were , Operational Basis , Global Humira Net Revenues Were , Global Skyrizi Net Revenues Were , Global Rinvoq Net Revenues Were , Hematologic Oncology Portfolio Were , Global Imbruvica Net Revenues Were , Global Venclexta Net Revenues Were , Neuroscience Portfolio Were , Global Botox Therapeutic Net Revenues Were , Global Vraylar Net Revenues , Aesthetics Portfolio Were , Global Botox Cosmetic Net Revenues Were , Global Juvederm Net Revenues Were , Share Related , Fourth Quarter Net Revenues , Excludes Any Unfavorable Impact Related , Botox Therapeutic , Botox Cosmetic , American College , Biologics License Application , Marketing Authorization Application , American Society , Annual Meeting , Janssen Biotech , Gedeon Richter , Chronic Migraine Epidemiology , Hotspot Therapeutics , Anima Biotech , Allergan Aesthetics , Investor Relations , Private Securities Litigation Reform Act , Quarterly Reports , Ended December , Months Ended December , Abbvie ,